dasapharm limited
dasapharm limited Company Information
Company Number
09325869
Next Accounts
Sep 2025
Shareholders
sia ratiobalt
dmitri dan spivak
Group Structure
View All
Industry
Wholesale of pharmaceutical goods
Registered Address
2nd floor, 201 haverstock hill, london, NW3 4QG
Website
dasapharm.comdasapharm limited Estimated Valuation
Pomanda estimates the enterprise value of DASAPHARM LIMITED at £1.6m based on a Turnover of £3.3m and 0.5x industry multiple (adjusted for size and gross margin).
dasapharm limited Estimated Valuation
Pomanda estimates the enterprise value of DASAPHARM LIMITED at £0 based on an EBITDA of £-9.5k and a 5.03x industry multiple (adjusted for size and gross margin).
dasapharm limited Estimated Valuation
Pomanda estimates the enterprise value of DASAPHARM LIMITED at £0 based on Net Assets of £-101.4k and 1.92x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Dasapharm Limited Overview
Dasapharm Limited is a live company located in london, NW3 4QG with a Companies House number of 09325869. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in November 2014, it's largest shareholder is sia ratiobalt with a 50% stake. Dasapharm Limited is a established, small sized company, Pomanda has estimated its turnover at £3.3m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Dasapharm Limited Health Check
Pomanda's financial health check has awarded Dasapharm Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 6 areas for improvement. Company Health Check FAQs
3 Strong
3 Regular
6 Weak
Size
annual sales of £3.3m, make it smaller than the average company (£24.4m)
- Dasapharm Limited
£24.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 77%, show it is growing at a faster rate (5.3%)
- Dasapharm Limited
5.3% - Industry AVG
Production
with a gross margin of 29.5%, this company has a comparable cost of product (29.5%)
- Dasapharm Limited
29.5% - Industry AVG
Profitability
an operating margin of -0.4% make it less profitable than the average company (4.1%)
- Dasapharm Limited
4.1% - Industry AVG
Employees
with 6 employees, this is below the industry average (36)
- Dasapharm Limited
36 - Industry AVG
Pay Structure
on an average salary of £81.1k, the company has an equivalent pay structure (£81.1k)
- Dasapharm Limited
£81.1k - Industry AVG
Efficiency
resulting in sales per employee of £547.9k, this is less efficient (£654.7k)
- Dasapharm Limited
£654.7k - Industry AVG
Debtor Days
it gets paid by customers after 83 days, this is later than average (57 days)
- Dasapharm Limited
57 days - Industry AVG
Creditor Days
its suppliers are paid after 46 days, this is slower than average (30 days)
- Dasapharm Limited
30 days - Industry AVG
Stock Days
it holds stock equivalent to 59 days, this is in line with average (64 days)
- Dasapharm Limited
64 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 18 weeks, this is more cash available to meet short term requirements (11 weeks)
18 weeks - Dasapharm Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 105.6%, this is a higher level of debt than the average (54.3%)
105.6% - Dasapharm Limited
54.3% - Industry AVG
DASAPHARM LIMITED financials
Dasapharm Limited's latest turnover from December 2023 is estimated at £3.3 million and the company has net assets of -£101.4 thousand. According to their latest financial statements, we estimate that Dasapharm Limited has 6 employees and maintains cash reserves of £668.7 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Nov 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | |||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Nov 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,559 | 5,235 | 9,676 | 12,436 | |||||
| Intangible Assets | |||||||||
| Investments & Other | |||||||||
| Debtors (Due After 1 year) | |||||||||
| Total Fixed Assets | 1,559 | 5,235 | 9,677 | 12,436 | |||||
| Stock & work in progress | 379,214 | 98,940 | 30,222 | 2,000 | |||||
| Trade Debtors | 751,761 | 590,520 | 348,714 | 133,990 | 311,909 | 1,220,173 | 542,527 | 1 | |
| Group Debtors | |||||||||
| Misc Debtors | 6,114 | 1,890 | 309 | 107 | |||||
| Cash | 668,722 | 512,375 | 250,790 | 157,438 | |||||
| misc current assets | |||||||||
| total current assets | 1,805,812 | 1,203,726 | 630,036 | 293,535 | 311,909 | 1,220,173 | 542,527 | 1 | |
| total assets | 1,807,371 | 1,208,961 | 639,713 | 305,971 | 311,909 | 1,220,173 | 542,527 | 1 | |
| Bank overdraft | |||||||||
| Bank loan | |||||||||
| Trade Creditors | 295,570 | 352,864 | 184,866 | 83,841 | 294,929 | 1,210,160 | 539,164 | ||
| Group/Directors Accounts | 1,065,086 | ||||||||
| other short term finances | |||||||||
| hp & lease commitments | |||||||||
| other current liabilities | 548,104 | 970,824 | 589,012 | 355,346 | |||||
| total current liabilities | 1,908,760 | 1,323,689 | 773,879 | 439,188 | 294,929 | 1,210,160 | 539,164 | ||
| loans | |||||||||
| hp & lease commitments | |||||||||
| Accruals and Deferred Income | 1,989 | 2,206 | 495 | ||||||
| other liabilities | |||||||||
| provisions | |||||||||
| total long term liabilities | 1,989 | 2,207 | 495 | ||||||
| total liabilities | 1,908,760 | 1,323,689 | 773,879 | 439,188 | 296,918 | 1,212,366 | 539,659 | ||
| net assets | -101,389 | -114,728 | -134,166 | -133,216 | 14,991 | 7,806 | 2,868 | 1 | |
| total shareholders funds | -101,389 | -114,728 | -134,166 | -133,216 | 14,991 | 7,806 | 2,868 | 1 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Nov 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | 3,676 | 3,676 | 3,843 | 1,997 | |||||
| Amortisation | |||||||||
| Tax | |||||||||
| Stock | 280,274 | 68,718 | 28,223 | 2,000 | |||||
| Debtors | 165,465 | 243,387 | 214,926 | -177,812 | -908,263 | 677,646 | 542,526 | ||
| Creditors | -57,295 | 167,998 | 101,025 | -211,088 | -915,231 | 670,996 | 539,164 | ||
| Accruals and Deferred Income | -422,720 | 381,812 | 233,666 | 353,357 | -217 | 1,711 | 495 | ||
| Deferred Taxes & Provisions | |||||||||
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | |||||||||
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | |||||||||
| Group/Directors Accounts | 1,065,086 | ||||||||
| Other Short Term Loans | |||||||||
| Long term loans | |||||||||
| Hire Purchase and Lease Commitments | |||||||||
| other long term liabilities | |||||||||
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | 156,348 | 261,585 | 93,352 | 157,438 | |||||
| overdraft | |||||||||
| change in cash | 156,348 | 261,585 | 93,352 | 157,438 |
dasapharm limited Credit Report and Business Information
Dasapharm Limited Competitor Analysis
Perform a competitor analysis for dasapharm limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in NW3 area or any other competitors across 12 key performance metrics.
dasapharm limited Ownership
DASAPHARM LIMITED group structure
Dasapharm Limited has no subsidiary companies.
Ultimate parent company
DASAPHARM LIMITED
09325869
dasapharm limited directors
Dasapharm Limited currently has 2 directors. The longest serving directors include Mr Dimitri Mevzos (Jun 2015) and Mr Alexander Katzman (Jan 2016).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Dimitri Mevzos | England | 52 years | Jun 2015 | - | Director |
| Mr Alexander Katzman | England | 54 years | Jan 2016 | - | Director |
P&L
December 2023turnover
3.3m
+23%
operating profit
-13.2k
0%
gross margin
29.6%
+1.8%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-101.4k
-0.12%
total assets
1.8m
+0.49%
cash
668.7k
+0.31%
net assets
Total assets minus all liabilities
dasapharm limited company details
company number
09325869
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
November 2014
age
11
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
-
address
2nd floor, 201 haverstock hill, london, NW3 4QG
Bank
-
Legal Advisor
-
dasapharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to dasapharm limited.
dasapharm limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for DASAPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.
dasapharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
